Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Exclusion Criteria

• •No previous treatment with ZD1839 or any other EGFR-targeted therapy
• •No progressive disease after combined therapy for locally advanced NSCLC
• •No presence of metastatic disease
• •No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
• •Any unresolved chronic toxicity from previous anticancer therapy.